Clinical Trial Update: Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension. [Phase 4]

View source ↗

Summary

This Phase 4 trial compares once-daily 300 mg aliskiren to twice-daily 150 mg in adults with essential hypertension to evaluate efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• Tekturna (aliskiren)

Snippet

Sponsor: Novartis | Conditions: Essential Hypertension | Phase 4 | Status: COMPLETED | Results posted: 2011-06-15